↓ Skip to main content
What is this page? Embed badge

Gene and Cell Therapies for Beta-Globinopathies

Overview of attention for book
Cover of 'Gene and Cell Therapies for Beta-Globinopathies'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Clinical Features of β-Thalassemia and Sickle Cell Disease
  3. Altmetric Badge
    Chapter 2 Genetic Basis and Genetic Modifiers of β-Thalassemia and Sickle Cell Disease
  4. Altmetric Badge
    Chapter 3 Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease
  5. Altmetric Badge
    Chapter 4 Allogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia
  6. Altmetric Badge
    Chapter 5 Alternative Donor/Unrelated Donor Transplants for the β-Thalassemia and Sickle Cell Disease
  7. Altmetric Badge
    Chapter 6 Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia
  8. Altmetric Badge
    Chapter 7 Reactivation of Fetal Hemoglobin for Treating β-Thalassemia and Sickle Cell Disease
  9. Altmetric Badge
    Chapter 8 Genome Editing for the β-Hemoglobinopathies
  10. Altmetric Badge
    Chapter 9 Gene and Cell Therapy for β-Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier
Attention for Chapter 9: Gene and Cell Therapy for β-Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
25 Mendeley
Summary X Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Gene and Cell Therapy for β-Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier
Chapter number 9
Book title
Gene and Cell Therapies for Beta-Globinopathies
Published in
Advances in experimental medicine and biology, November 2017
DOI 10.1007/978-1-4939-7299-9_9
Pubmed ID
29127683
Book ISBNs
978-1-4939-7297-5, 978-1-4939-7299-9
Authors

Papapetrou, Eirini P., Eirini P. Papapetrou

Abstract

In recent years, breakthroughs in human pluripotent stem cell (hPSC) research, namely cellular reprogramming and the emergence of sophisticated genetic engineering technologies, have opened new frontiers for cell and gene therapy. The prospect of using hPSCs, either autologous or histocompatible, as targets of genetic modification and their differentiated progeny as cell products for transplantation, presents a new paradigm of regenerative medicine of potential tremendous value for the treatment of blood disorders, including beta-thalassemia (BT) and sickle cell disease (SCD). Despite advances at a remarkable pace and great promise, many roadblocks remain before clinical translation can be realistically considered. Here we discuss the theoretical advantages of cell therapies utilizing hPSC derivatives, recent proof-of-principle studies and the main challenges towards realizing the potential of hPSC therapies in the clinic.

View on publisher site
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
 Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 25 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 20%
Other 2 8%
Student > Master 2 8%
Lecturer 1 4%
Professor 1 4%
Other 3 12%
Unknown 11 44%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 9 36%
Medicine and Dentistry 3 12%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Arts and Humanities 1 4%
Unknown 11 44%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 November 2017.
All research outputs
#15,483,026
of 23,007,887 outputs
Outputs from Advances in experimental medicine and biology
#2,514
of 4,961 outputs
Outputs of similar age
#204,641
of 326,841 outputs
Outputs of similar age from Advances in experimental medicine and biology
#15
of 29 outputs
Altmetric has tracked 23,007,887 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,961 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,841 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.